Steensma, David P.
Ajax Therapeutics,
United States
2025 Rank: 12226
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 438 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 12226 | 11358 |
| Total Cites | 16593 | 19892 |
| H-index | 67 | 74 |
| Hm-index | 29 | 31 |
| Number of Single Authored Papers | 98 | 98 |
| Total Cites to Single Authored Papers | 1263 | 1400 |
| Number of Single+First Authored Papers | 205 | 205 |
| Total Cites to Single+First Authored Papers | 5340 | 6133 |
| Number of Single+First+Last Authored Papers | 332 | 332 |
| Total Cites to Single+First+Last Authored Papers | 6894 | 7896 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 12790 | 14300 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.39 |
| Self-Citation Percentage |
16.58%
|
|
Steensma, David P.
Ajax Therapeutics,
United States
2024 Rank: 13272
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 479 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 13272 | 11937 |
| Total Cites | 14904 | 17963 |
| H-index | 61 | 71 |
| Hm-index | 28 | 29 |
| Number of Single Authored Papers | 94 | 94 |
| Total Cites to Single Authored Papers | 1166 | 1296 |
| Number of Single+First Authored Papers | 208 | 208 |
| Total Cites to Single+First Authored Papers | 4914 | 5675 |
| Number of Single+First+Last Authored Papers | 333 | 333 |
| Total Cites to Single+First+Last Authored Papers | 6332 | 7291 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 11537 | 12945 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.39 |
| Self-Citation Percentage |
17.03%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2023 Rank: 14394
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 532 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 14394 | 13048 |
| Total Cites | 13162 | 15915 |
| H-index | 58 | 66 |
| Hm-index | 26 | 28 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 1061 | 1189 |
| Number of Single+First Authored Papers | 201 | 201 |
| Total Cites to Single+First Authored Papers | 4456 | 5183 |
| Number of Single+First+Last Authored Papers | 325 | 325 |
| Total Cites to Single+First+Last Authored Papers | 5743 | 6658 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 10301 | 11593 |
| Ratio of Total Citations to Distinct Citing Papers | 1.28 | 1.37 |
| Self-Citation Percentage |
17.30%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2022 Rank: 16104
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 606 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16104 | 14212 |
| Total Cites | 11397 | 13800 |
| H-index | 53 | 61 |
| Hm-index | 25 | 27 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 924 | 1049 |
| Number of Single+First Authored Papers | 196 | 196 |
| Total Cites to Single+First Authored Papers | 3964 | 4649 |
| Number of Single+First+Last Authored Papers | 317 | 317 |
| Total Cites to Single+First+Last Authored Papers | 5104 | 5959 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 9007 | 10152 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.36 |
| Self-Citation Percentage |
17.41%
|
|
Steensma, David P.
Dana-Farber Cancer Institute,
United States
2021 Rank: 16796
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 625 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16796 | 15527 |
| Total Cites | 10499 | 12741 |
| H-index | 51 | 57 |
| Hm-index | 24 | 26 |
| Number of Single Authored Papers | 91 | 91 |
| Total Cites to Single Authored Papers | 855 | 966 |
| Number of Single+First Authored Papers | 190 | 190 |
| Total Cites to Single+First Authored Papers | 3693 | 4333 |
| Number of Single+First+Last Authored Papers | 310 | 310 |
| Total Cites to Single+First+Last Authored Papers | 4766 | 5564 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 8380 | 9472 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.35 |
| Self-Citation Percentage |
17.60%
|
|
Steensma, David P.
Dana-Farber Cancer Institute,
United States
2020 Rank: 20744
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 738 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 20744 | 18552 |
| Total Cites | 8660 | 10626 |
| H-index | 45 | 49 |
| Hm-index | 22 | 24 |
| Number of Single Authored Papers | 88 | 88 |
| Total Cites to Single Authored Papers | 689 | 794 |
| Number of Single+First Authored Papers | 182 | 182 |
| Total Cites to Single+First Authored Papers | 3194 | 3802 |
| Number of Single+First+Last Authored Papers | 294 | 294 |
| Total Cites to Single+First+Last Authored Papers | 4098 | 4853 |
| Composite Score | 3 | 4 |
| Number of Distinct Citing Papers | 7005 | 7974 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.33 |
| Self-Citation Percentage |
18.50%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.